Overview / Abstract: |
This is part 2 of a 2-part activity. Outcomes for patients with pulmonary arterial hypertension (PAH) have improved over the last decade, but mortality remains unacceptably high, particularly among patients with more severe disease. Many patients with PAH continue to experience debilitating symptoms despite medical treatment. In this activity, Dr. Ioana Preston focuses on how clinical trial design in PAH is evolving to become more relevant to patients and clinicians through the use of multicomponent improvement endpoints. This activity consists of text that can be read at your own pace interspersed with short videos of Dr. Preston highlighting take-home points. |
Expiration |
Aug 22, 2023 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME, Respiratory Therapy CE |
Format |
Online |
Credits / Hours |
0.5 |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Ioana Preston, MD |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Merck Sharp & Dohme Corp. |
Keywords / Search Terms |
CMEology CMEology Pulmonary arterial hypertension PAH Pulmonary hypertension Endothelin receptor antagonist Guanylate cyclase stimulator Prostacyclin analogue Selective prostacyclin receptor agonist BMPR-II signaling CME, CMEology, epocrates, Free CE, Free CME |